Annie Yessaian, MD

Clinical Assistant Professor of Obstetrics & Gynecology (Clinician Educator)

Director of the Gynecology/Oncology Outreach Program

Image of Annie Yessaian, MD
Is this your profile? Click to edit

Overview

Dr. Yessaian graduated from the University of Baghdad Medical School, Iraq in 1989 with high honors. She then further trained in a rotating internship for two years in Baghdad. Dr. Yessaian then joined the residency training program in general surgery at Maimonides Medical Center-Brooklyn NY, where she also received four additional years of obstetrics & gynecology training. She completed her residency in 1998, receiving the award of “Best Chief Resident of the Year. Dr. Yessaian received further training in a research fellowship in molecular biology at Memorial Sloan Kettering Cancer Center, studying platinum resistance in ovarian cancer. She then joined the gynecologic oncology fellowship program at UC Irvine for four more years, where her research areas included angiogenesis in ovarian cancer. Dr. Yessaian received the Society of Gynecologic Oncologist award for best paper presented by a fellow in 2002. In 2004, Dr. Yessaian joined USC as an Assistant professor of clinical Ob-gyn, Gynecologic Oncology. She practices the full scope of gynecological oncology from minimally invasive robotic and fertility sparing surgery, to the ultra-radical surgeries and including chemotherapy, immunotherapy and clinical trials enrollment.

Publications

  • Temporal trends of failure-to-rescue following perioperative complications in vulvar cancer surgery in the United States Gynecol Oncol. 2023 Oct; 177:1-8. . View in PubMed
  • Two staged phase II clinical trial of Eribulin monotherapy in advanced or recurrent cervical cancer Gynecol Oncol. 2023 06; 173:49-57. . View in PubMed
  • Our Space of Morrow Int J Gynecol Cancer. 2022 Nov 21. . View in PubMed
  • Side-to-end reanastomosis after low-anterior resection (STELAR): Outcomes, feasibility, and description of procedure performed by a gynecologic oncology service J Surg Oncol. 2022 Sep; 126(3):563-570. . View in PubMed
  • Association between sentinel lymph node biopsy and micrometastasis in endometrial cancer Eur J Obstet Gynecol Reprod Biol. 2022 Aug; 275:91-96. . View in PubMed
  • Trends and characteristics of ovarian conservation at hysterectomy for young women with cervical cancer Eur J Obstet Gynecol Reprod Biol. 2022 Jun; 273:59-64. . View in PubMed
  • Population-level uptake of neoadjuvant chemotherapy for stage IVB endometrial cancer Gynecol Oncol. 2022 06; 165(3):428-436. . View in PubMed
  • Correction to: Adjuvant hysterectomy following primary chemoradiation for stage IB2 and IIA2 cervical cancer: a retrospective comparison of complications for open versus minimally invasive surgery Radiat Oncol. 2021 Aug 25; 16(1):162. . View in PubMed
  • Adjuvant hysterectomy following primary chemoradiation for stage IB2 and IIA2 cervical cancer: a retrospective comparison of complications for open versus minimally invasive surgery Radiat Oncol. 2021 Jun 29; 16(1):123. . View in PubMed
  • Implementation of multidisciplinary practice change to improve outcomes for women with placenta accreta spectrum Eur J Obstet Gynecol Reprod Biol. 2020 Mar; 246:194-196. . View in PubMed
  • Non-prescription cannabis use for symptom management amongst women with gynecologic malignancies Gynecol Oncol Rep. 2019 Nov; 30:100497. . View in PubMed
  • Overexpression of HOMER2 predicts better outcome in low-grade endometrioid endometrial adenocarcinoma Pathology. 2018 Aug; 50(5):499-503. . View in PubMed
  • Patient compliance for postoperative radiotherapy and survival outcome of women with stage I endometrioid endometrial cancer J Surg Oncol. 2017 Sep; 116(4):482-491. . View in PubMed
  • Prognosis of women with apparent stage I endometrial cancer who had supracervical hysterectomy Gynecol Oncol. 2017 Apr; 145(1):41-49. . View in PubMed
  • Endoplasmic reticulum stress in complex atypical hyperplasia as a possible predictor of occult carcinoma and progestin response Gynecol Oncol. 2016 Dec; 143(3):650-654. . View in PubMed
  • Microfocus of Anaplastic Carcinoma Arising in Mural Nodule of Ovarian Mucinous Borderline Tumor With Very Rapid and Fatal Outcome Int J Gynecol Pathol. 2016 Jul; 35(4):348-51. . View in PubMed
  • Predictive Factor of Conversion to Laparotomy in Minimally Invasive Surgical Staging for Endometrial Cancer Int J Gynecol Cancer. 2016 Feb; 26(2):290-300. . View in PubMed
  • Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C Clin Immunol. 2015 Dec; 161(2):197-208. . View in PubMed
  • Clinical Implications of Marker Expression of Carcinoma-Associated Fibroblasts (CAFs) in Patients with Epithelial Ovarian Carcinoma After Treatment with Neoadjuvant Chemotherapy Cancer Microenviron. 2014 Aug; 7(1-2):33-9. . View in PubMed
  • Predictive model of venous thromboembolism in endometrial cancer Gynecol Oncol. 2013 Mar; 128(3):544-51. . View in PubMed
  • Histologic parameters predictive of disease outcome in women with advanced stage ovarian carcinoma treated with neoadjuvant chemotherapy Transl Oncol. 2012 Dec; 5(6):469-74. . View in PubMed
  • Significance of perioperative infection in survival of patients with ovarian cancer Int J Gynecol Cancer. 2012 Feb; 22(2):245-53. . View in PubMed
  • Long-term pegylated liposomal doxorubicin use and oromaxillary squamous cell carcinoma in endometrial cancer Oncologist. 2012; 17(12):1598-9. . View in PubMed
  • Population characteristics in cervical cancer trials: search for external validity Am J Obstet Gynecol. 2005 Feb; 192(2):407-13. . View in PubMed
  • Radical hysterectomy followed by tailored postoperative therapy in the treatment of stage IB2 cervical cancer: feasibility and indications for adjuvant therapy Gynecol Oncol. 2004 Jul; 94(1):61-6. . View in PubMed